Zimmer Biomet Holdings, Inc.
ZBH
Positions held
Your positionsZBH isn't in your positions.
Add it to see shares, cost, and P&L here.
Bull / bear case
Site-generated summary from fundamentals, news, and score — not investment advice. As of 2026-10-07.
- Zimmer Biomet is well-positioned in the medical devices industry with a strong focus on innovation and product development, which can drive future growth.
- In Q2 2026, revenue increased by 4% compared to the previous quarter, reaching $2.2 billion.
- The company reported a gross margin of 70.8% in Q2 2026, demonstrating its ability to maintain profitability.
- The current market sentiment is negative, with a 'Strong Sell' signal indicating potential challenges ahead for investors.
- The company's score is -16.00, reflecting a bearish trend with indicators such as MACD and Supertrend showing downward momentum.
- In Q2 2026, the gross margin decreased to 70.8%, down from 72.4% in the prior quarter, suggesting potential cost pressures.
Fundamentals
| Market cap | $16.95B | Enterprise value | $24.10B | Trailing P/E | 21.57 | Forward P/E | 9.80 |
| PEG | 0.56 | Price / book | 1.34 | Beta | 0.49 | Dividend yield | 1.08% |
| Revenue growth | 4.8% | Earnings growth | 33.8% | Gross margin | 69.5% | Operating margin | 18.0% |
| Profit margin | 9.5% | ROE | 6.4% | ROA | 3.9% | Debt / equity | 0.60 |
| Current ratio | 1.69 | Free cash flow | $1.07B | Analyst recommendation | buy | Mean target | $107.23 |
| 52w high | $106.88 | 52w low | $79.12 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | |
|---|---|---|---|---|---|---|
| Revenue | $2.2B | $2.1B | $2.2B | $2.0B | $2.1B | — |
| Op margin | 17.2% | 18.9% | 12.6% | 16.9% | 19.1% | — |
| Net income | $198M | $238M | $139M | $231M | $153M | — |
| Gross margin | 70.8% | 72.4% | 64.7% | 72.1% | 71.5% | — |
| Gross profit | $1.5B | $1.5B | $1.5B | $1.4B | $1.5B | — |
| Operating income | $374M | $395M | $283M | $338M | $396M | — |
- Revenue +4% vs prior quarter ($2.2B vs $2.1B).
- Gross margin 70.8% (was 72.4% prior quarter).
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $8.2B | $7.7B | $7.4B | $6.9B | — |
| Op margin | 16.5% | 19.9% | 19.6% | 17.2% | — |
| Net income | $705M | $904M | $1.0B | $231M | — |
| Gross margin | 69.7% | 71.5% | 71.8% | 70.9% | — |
| Gross profit | $5.7B | $5.5B | $5.3B | $4.9B | — |
| Operating income | $1.4B | $1.5B | $1.5B | $1.2B | — |
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-10-09 · Leerink Partners Adjusts Price Target on Zimmer Biomet to $97 From $106
2026-10-07 · Evercore ISI Adjusts Zimmer Biomet Price Target to $115 From $110
2026-10-07 · Flutter upgraded, AppFolio downgraded: Wall Street's top analyst calls
2026-10-06 · What Could Lift ISRG Stock?
2026-10-06 · Are Investors Undervaluing Baxter International (BAX) Right Now?
2026-10-06 · Zimmer Biomet Announces Webcast and Conference Call of Third Quarter 2026 Financial Results
2026-10-02 · Are You Overpaying For Intuitive Surgical Stock Versus Its Rivals?
2026-09-29 · Do You Really Understand ISRG Stock's Risk?
2026-09-28 · Is ResMed A Better Way Than Stryker To Own Medical Device Growth?
2026-09-26 · Zimmer Biomet (ZBH): Buy, Sell, or Hold Post Q2 Earnings?
2026-09-25 · Zimmer Biomet Holdings (ZBH) Pushes Cost Reset Plans, Is It Still 17% Below Fair Value?
2026-09-24 · Can This Number Push ISRG Stock Higher?
Price (daily)
Full chart · RSI · MACD · patterns